Pharmacogenomic profiling of adrenergic receptors holds potential for personalizing beta-blocker therapy in heart failure and hypertension, though clinical application remains complex due to gene-drug interactions and racial differences.
May support pharmacogenomic beta-blocker personalization in HF and hypertension; leaves open prospective validation before clinical use.
Cardiovascular medicine is a leading area of pharmacogenomics (PGx). A number of PGx studies have linked genetic polymorphisms to patients' response to the drugs in the pharmacotherapy against cardiovascular diseases. Among them, PGx of adrenoceptors is one of the most important fields, because adrenergic networks play important roles in cardiovascular systems. The excess of adrenergic stimuli result in cardiovascular disorders, such as hypertension and heart failure (HF). One of the aims of PGx studies of adrenoreceptors is the personalization of -blocker therapy. In this review, we have described biological and clinical impacts on genetic variants of adrenoreceptors, some of which have showed clear association with the reduction in heart rate and blood pressure in response to -blockers. Beyond anti-hypertension therapy, PGx of adrenoreceptors would contribute to the individualization of pharmacotherapy against HF.
No takes yet. Share an insight, caveat, or question.
Nonen et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: